Last reviewed · How we verify
NCT05397028: DRS
Weight Management for the Remission of Type 2 Diabetes Using a Proprietary Meal Replacement System- Diabetes Remission Study (DRS)
NA trial testing Meal replacement system in Obesity in 3 participants. Terminated before completion.
14 March 2023
Quick facts
| Lead sponsor | Loma Linda University |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 3 |
| Start date | 8 December 2022 |
| Primary completion | 14 March 2023 |
| Estimated completion | 14 March 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Meal replacement system
- Intensive lifestyle Intervention
Conditions studied
- Obesity — all drugs for Obesity →
- Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →
Sponsor
Loma Linda University
Who can join
Adults 25 to 65, any sex, with Obesity or Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A three month meal replacement dietary system which combines meal replacements and self-prepared meals which hypothetically will result in Diabetes remission in \>30% of intervention subjects To assess the efficacy of which patients with Type 2 Diabetes (non insulin dependent) can be brought into a optimal A1C remission state without the use of medications by achieving clinically significant weight loss (\>20-30 pounds) using a proprietary meal replacement system associated with a 3-month intensive lifestyle program.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05397028
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obesity
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
- NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
Other Loma Linda University trials
Trials by the same sponsor.
- NCT07213843 — Combined Circulatory and Dietary Interventions for Neuropathy · NA · not yet recruiting
- NCT07130812 — Blood Flow Restriction Training as a Targeted Intervention for Rowers With Back Pain. · NA · recruiting
- NCT06673342 — Effectiveness of a Nutritional Counseling Tool in Reducing the Amount and Frequency of Sugar Intake · NA · completed
- NCT06445842 — Short-term Circuit Training on Muscle Mass and Quality of Life in Sedentary Postmenopausal Women · NA · recruiting
- NCT07396831 — Necessity of Post-operative Eye Drops · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05397028 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Loma Linda University
- Last refreshed: 19 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05397028.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing